Dan Deardorf

Dan has over 25 years in biopharma development and commercialization. His broad global experience spans all stages of biomedical development across multiple platforms including biomaterials, small molecules and cell therapy.

Previous to his CEO position at Glycologix, Dan was a trusted leader and builder of world-class teams at Genzyme and Flexion Therapeutics. Dan founded the Flexion commercial organization and built the team which architected the successful launch Flexion’s flagship product Zilretta®, while partnering with the CEO and CFO to raise nearly $600M in follow-on equity and convertible debt offerings. At Genzyme, Dan held a variety of leadership positions across several functions. Dan has an MBA from the Wharton School of Management at the University of Pennsylvania and B.S. in Biochemistry.